Vitaprost, 20 mg 20 pcs

Vitaprost® has organotropic effect on the prostate.

It reduces degree of edema and leucocytic infiltration of the prostate, normalizes secretory function of epithelial cells, increases the number of lecithin granules in the atinus secretion, stimulates muscle tone of the bladder.

It improves microcirculation in the prostate due to reduction of thrombogenesis, anti-aggregant activity, prevents development of venous thrombosis in the prostate.

Based on data of clinical trials it was proved that Vitaprost® moderately decreases prostate volume.

The drug reduces severity of obstructive and irritative symptoms of benign prostatic hyperplasia which is revealed through the increase of maximum and average volume rates of urine flow and reduction of residual urine volume.

The data of clinical trials have proved that Vitaprost® reduces the probability of exacerbations of chronic abacterial prostatitis and causes no changes in indexes of clinical and biochemical blood analysis and general urine analysis.

The efficiency of Vitaprost® application for prevention of exacerbations of chronic abacterial prostatitis according to evaluations of research doctors is 97,5 %.

Vitaprost® normalizes the parameters of prostate secretion and ejaculate. It reduces pain and discomfort caused by prostatitis, eliminates dysuria and improves copulatory function.

Indications

Chronic abacterial prostatitis.
Prevention of exacerbations of chronic abacterial prostatitis.
Benign prostatic hyperplasia.
Conditions before and after surgical interventions on the prostate gland.

Pharmacological effect

Vitaprost® has an organotropic effect on the prostate gland.

Reduces the degree of edema, leukocyte infiltration of the prostate gland, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secretion of the acini, stimulates the muscle tone of the bladder.

Improves microcirculation in the prostate gland by reducing thrombus formation, antiplatelet activity, and prevents the development of venule thrombosis in the prostate gland.

Based on clinical research data, it has been proven that Vitaprost® moderately reduces the volume of the prostate gland.

The drug reduces the severity of obstructive and irritative symptoms in benign prostatic hyperplasia, which is expressed in an increase in the maximum and average volumetric flow rates of urine and a decrease in the volume of residual urine.

Data from clinical studies have proven that the use of Vitaprost® reduces the likelihood of developing exacerbations of chronic abacterial prostatitis, does not cause changes in clinical and biochemical blood tests, and general urinalysis.

The effectiveness of the use of the drug Vitaprost® for the prevention of exacerbations of chronic abacterial prostatitis, according to the estimates of medical researchers, is 97.5%.

Vitaprost® normalizes the parameters of prostate secretion and ejaculate. Reduces pain and discomfort caused by prostatitis, eliminates dysuric symptoms, improves copulative function.

Special instructions

Treatment of chronic prostatitis and conditions before and after surgical interventions on the prostate gland should be comprehensive, involving, along with the prescription of Vitaprost® tablets, the use of other groups of medications and non-drug treatment methods.

Impact on the ability to drive vehicles and operate machinery

Does not affect the ability to drive a car or use other machinery.

Active ingredient

Prostate extract

Composition

One tablet contains:

Active substance:

Prostate extract – 100 mg (in terms of water-soluble peptides – 20 mg);

Excipients:

Sucrose – 28,500 mg,

Lactose monohydrate – 7.125 mg,

Calcium stearate monohydrate – 2,500 mg,

Crospovidone – 9.275 mg,

Microcrystalline cellulose – up to 102,600 mg;

Shell composition:

Acrylic (methacrylic acid and ethyl acrylate copolymer [1:1],

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Extremely rare – allergic reactions.

If any of the side effects listed above get worse or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

If you are taking any other medications, you should consult your doctor before starting treatment.

Cases of interaction or incompatibility with other drugs have not been described.

Overdose

No cases of drug overdose have been reported.

Complete set of goods

Enteric-coated tablets, 20 mg. 10 tablets per blister pack made of polyvinyl chloride or polyvinyl chloride/polyvinylidene chloride film and printed varnished aluminum foil. 1, 2 or 3 blisters along with instructions for medical use of the medicinal product in a cardboard pack

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Nizhpharm JSC, Russia